Journal of Pharmacy And Bioallied Sciences
Journal of Pharmacy And Bioallied Sciences Login  | Users Online: 1644  Print this pageEmail this pageSmall font sizeDefault font sizeIncrease font size 
    Home | About us | Editorial board | Search | Ahead of print | Current Issue | Past Issues | Instructions | Online submission

    Article Cited by others


Patent protection strategies

Gupta Himanshu, Kumar Suresh, Roy Saroj Kumar, Gaud R S

Year : 2010| Volume: 2| Issue : 1 | Page no: 2-7

   This article has been cited by
1 Metastable Crystallization by Drop Impact
Akari Nishigaki, Mihoko Maruyama, Shun-ichi Tanaka, Hiroshi Y. Yoshikawa, Masayuki Imanishi, Masashi Yoshimura, Yusuke Mori, Kazufumi Takano
Crystals. 2022; 12(8): 1104
[Pubmed]  [Google Scholar] [DOI]
2 Chiral Switch: Between Therapeutical Benefit and Marketing Strategy
Gabriel Hancu, Adriana Modroiu
Pharmaceuticals. 2022; 15(2): 240
[Pubmed]  [Google Scholar] [DOI]
3 Crystallization of Form II Paracetamol with the Assistance of Carboxylic Acids toward Batch and Continuous Processes
Kuan-Lin Yeh, Hung-Lin Lee, Tu Lee
Pharmaceutics. 2022; 14(5): 1099
[Pubmed]  [Google Scholar] [DOI]
4 Healthcare Innovations
Shanmuganathan Padmavathi, Subhash Chandra Parija
Annals of SBV. 2022; 11(1): 1
[Pubmed]  [Google Scholar] [DOI]
5 Growth of Acetaminophen Polymorphic Crystals and Solution-Mediated Phase Transition from Trihydrate to Form II in Agarose Gel
Akari Nishigaki, Mihoko Maruyama, Shun-ichi Tanaka, Hiroshi Y. Yoshikawa, Masayuki Imanishi, Masashi Yoshimura, Yusuke Mori, Kazufumi Takano
Crystals. 2021; 11(9): 1069
[Pubmed]  [Google Scholar] [DOI]
6 Recent patents on therapeutic activities of xanthohumol: a prenylated chalconoid from hops (Humulus lupulus L.)
Diwakar Aggarwal, Sushil K Upadhyay, Raj Singh, Hardeep S Tuli
Pharmaceutical Patent Analyst. 2021; 10(1): 37
[Pubmed]  [Google Scholar] [DOI]
7 Pharmaceutical patenting in the European Union: reform or riddance
Livio Garattini, Marco Badinella Martini, Pier Mannuccio Mannucci
Internal and Emergency Medicine. 2021;
[Pubmed]  [Google Scholar] [DOI]
8 Pharmaceutical Patents in Europe: Radical Reforms Rather Than Getting Rid?
Livio Garattini, Bruno Finazzi
Applied Health Economics and Health Policy. 2021;
[Pubmed]  [Google Scholar] [DOI]
9 Fast 19F Magic Angle Spinning NMR Crystallography for Structural Characterization of Fluorine-Containing Pharmaceutical Compounds
Changmiao Guo, Matthew P. Fritz, Jochem Struppe, Sebastian Wegner, John Stringer, Ivan V. Sergeyev, Caitlin M. Quinn, Angela M. Gronenborn, Tatyana Polenova
Analytical Chemistry. 2021; 93(23): 8210
[Pubmed]  [Google Scholar] [DOI]
10 Advancements in the Delivery of Growth Factors and Cytokines for the Treatment of Cutaneous Wound Indications
Caitlin Berry-Kilgour, Jaydee Cabral, Lyn Wise
Advances in Wound Care. 2021; 10(11): 596
[Pubmed]  [Google Scholar] [DOI]
11 Approval policies for modifications to machine learning-based software as a medical device: A study of bio-creep
Jean Feng, Scott Emerson, Noah Simon
Biometrics. 2021; 77(1): 31
[Pubmed]  [Google Scholar] [DOI]
12 The Effects of Patent Extension and Take-Back Regulation on Green Pharmacy
Tianqin Shi, Nicholas C. Petruzzi, Dilip Chhajed
Manufacturing & Service Operations Management. 2021;
[Pubmed]  [Google Scholar] [DOI]
13 A Critical Discourse Analysis of Intellectual Property Rights Within NAFTA 1.0: Implications for NAFTA 2.0 and for Democratic (Health) Governance in Canada
Faisal Ali Mohamed, Claudia Chaufan
International Journal of Health Services. 2020; 50(3): 278
[Pubmed]  [Google Scholar] [DOI]
14 Repurposed molecules for antiepileptogenesis: Missing an opportunity to prevent epilepsy?
Pavel Klein, Alon Friedman, Mustafa Q. Hameed, Rafal M. Kaminski, Guy Bar-Klein, Henrik Klitgaard, Mathias Koepp, Sergiusz Jozwiak, David A. Prince, Alexander Rotenberg, Roy Twyman, Annamaria Vezzani, Michael Wong, Wolfgang Löscher
Epilepsia. 2020; 61(3): 359
[Pubmed]  [Google Scholar] [DOI]
15 Science and Business of Medicinal Chemistry: A “Bench-to-Bedside” Course for Nonmajors
Anna G. Wenzel, Steven Casper, Cooper J. Galvin, Grace E. Beck
Journal of Chemical Education. 2020; 97(2): 414
[Pubmed]  [Google Scholar] [DOI]
16 The Polymorphism of Drugs: New Approaches to the Synthesis of Nanostructured Polymorphs
Dmitry Chistyakov, Gleb Sergeev
Pharmaceutics. 2020; 12(1): 34
[Pubmed]  [Google Scholar] [DOI]
17 COVID-19: molecular targets, drug repurposing and new avenues for drug discovery
Mario Roberto Senger, Tereza Cristina Santos Evangelista, Rafael Ferreira Dantas, Marcos Vinicius da Silva Santana, Luiz Carlos Saramago Gonçalves, Lauro Ribeiro de Souza Neto, Sabrina Baptista Ferreira, Floriano Paes Silva-Junior
Memórias do Instituto Oswaldo Cruz. 2020; 115
[Pubmed]  [Google Scholar] [DOI]
18 The relationship between medical innovation and health expenditure before and after health reform
Songul Cinaroglu, Onur Baser
Health Policy and Technology. 2018; 7(4): 379
[Pubmed]  [Google Scholar] [DOI]
19 Intellectual property rights derived from academic research and their role in the modern bioeconomy—A guide for scientists.
Jan B. Krauss,David Kuttenkeuler
New Biotechnology. 2017;
[Pubmed]  [Google Scholar] [DOI]
20 Healthcare innovation and patent law’s ‘pharmaceutical privilege’: is there a pharmaceutical privilege? And if so, should we remove it?
Graham Dutfield
Health Economics, Policy and Law. 2017; : 1
[Pubmed]  [Google Scholar] [DOI]
21 Higher patient satisfaction with antidepressants correlates with earlier drug release dates across online user-generated medical databases
Scott Siskind,Roland C. Aydin,Punit Matta,Christian J. Cyron
Pharmacology Research & Perspectives. 2017; 5(5): e00355
[Pubmed]  [Google Scholar] [DOI]
22 A systems-level analysis of drug–target–disease associations for drug repositioning
Kayleigh D. Rutherford,Gaston K. Mazandu,Nicola J. Mulder
Briefings in Functional Genomics. 2017;
[Pubmed]  [Google Scholar] [DOI]
23 Between pharmaceutical patents and European patients: is a compromise still possible?
Livio Garattini,Anna Padula
Expert Opinion on Therapeutic Patents. 2017; : 1
[Pubmed]  [Google Scholar] [DOI]
24 Is Patent “Evergreening” Restricting Access to Medicine/Device Combination Products?
Reed F. Beall,Jason W. Nickerson,Warren A. Kaplan,Amir Attaran,Heinz Fehrenbach
PLOS ONE. 2016; 11(2): e0148939
[Pubmed]  [Google Scholar] [DOI]
25 Has Creative Destruction become more Destructive?
John Komlos
The B.E. Journal of Economic Analysis & Policy. 2016; 16(4)
[Pubmed]  [Google Scholar] [DOI]
26 National Trends in the Ambulatory Treatment of Hypertension in the United States, 1997-2012
Meijia Zhou,Matthew Daubresse,Randall S. Stafford,G. Caleb Alexander,Angelo Scuteri
PLOS ONE. 2015; 10(3): e0119292
[Pubmed]  [Google Scholar] [DOI]
27 Tripartite Conflicts of Interest and High Stakes Patent Extensions in the DSM-5
Lisa Cosgrove, Sheldon Krimsky, Emily E. Wheeler, Jenesse Kaitz, Scott B. Greenspan, Nicole L. DiPentima
Psychotherapy and Psychosomatics. 2014; 83(2): 106
[Pubmed]  [Google Scholar] [DOI]
28 Product lifecycle management through patents and regulatory strategies
Vandana Prajapati,Swagat Tripathy,Harish Dureja
Journal of Medical Marketing: Device, Diagnostic and Pharmaceutical Marketing. 2013; 13(3): 171
[Pubmed]  [Google Scholar] [DOI]
29 Enantioselectivity of mass spectrometry: Challenges and promises
Hanan Awad,Anas El-Aneed
Mass Spectrometry Reviews. 2013; : n/a
[Pubmed]  [Google Scholar] [DOI]
30 Necessity of Establishing Chemical Integrity of Polymorphs of Drug Substance Using a Combination of NMR, HPLC, Elemental Analysis, and Solid-State Characterization Techniques: Case Studies
Kamlesh D. Sawant,Tushar A. Naik
Organic Process Research & Development. 2013; 17(3): 519
[Pubmed]  [Google Scholar] [DOI]


Read this article